Setmelanotide Injectable Solution Suppliers & Bulk Manufacturers
Available Forms: Injectable Solution
Available Strengths: 4 mg/mL
Reference Brands: Imcivree(Us & EU)
Category:
Weight Loss drugs
Setmelanotide is a melanocortin-4 receptor agonist that regulates appetite and energy balance. It helps reduce hunger, support weight loss, and improve metabolic health in patients with rare genetic obesity syndromes. Benefits include appetite suppression, increased energy expenditure, and improved quality of life for affected individuals worldwide.
setmelanotide Injectable solution is available in Injectable Solution
and strengths such as 4 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, setmelanotide Injectable solution is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
setmelanotide Injectable solution can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Setmelanotide injectable solution, marketed as Imcivree, is approved in the US by the FDA and in the EU via EMA for treating obesity caused by rare genetic disorders such as POMC deficiency, PCSK1 deficiency, and Bardet-Biedl syndrome. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality data for timely approval, while the EMA ensures regional safety and manufacturing compliance. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports swift approval, safe administration, and global availability to help patients worldwide manage rare genetic obesity effectively.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing